About

The New Evidence team welcomes you to our website: New Evidence–Canadian Vision for Rheumatology. Our website and journal provide rheumatology specialists with scientific data from research presented at international and Canadian rheumatology conferences. A special feature, the Canadian perspective, gives key opinion leaders a forum to discuss recent developments in rheumatology and to comment on how these advances may shape Canadian clinical practice.

Our January 2012 issue presents coverage of the 2011 ACR/ ARHP Annual Scientific Meeting held in Chicago, Illinois, on November 6–9, 2011. This issue includes studies focusing on switching to tocilizumab monotherapy in patients with an inadequate response to disease modifying anti-rheumatic drugs (DMARDs) or biologics and switching to rituximab in patients failing tumour necrosis factor (TNF) inhibitors. We would like to thank Dr. Janet Pope, Dr. Denis Choquette, and Dr. John H. Stone for their Canadian and international perspectives, and Dr. Jeffrey R. Curtis and Dr. Shouvik Dass for their investigator commentaries.

We invite you to join us to receive the print version of New Evidence. Visit our website often for more reports on current research, downloadable slide presentations on various topics, and future online issues of our journal.

In This Issue

TOCILIZUMAB IN RA TREATMENT Tocilizumab monotherapy is a safe and effective treatment option

JUVENILE IDIOPATHIC ARTHRITIS Current biologic and non-biologic options for sJIA therapy

RITUXIMAB IN RA TREATMENT Switching to rituximab is safe and effective in patients failing TNF inhibitors

VASCULITIS Updates on the efficacy of rituximab in systemic vasculitis